MedTrace Logo

Clinical Trial to Evaluate the Efficacy and Safety of Recombinant Human Neuregulin-1 for Subcutaneous Administration in Patients With Chronic Systolic Heart Failure

NCT01214096 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2017-12-21

No results posted yet for this study

Summary

Evaluate the Efficacy and Safety of Recombinant Human Neuregulin-1 for Subcutaneous Administration in Patients With Chronic Systolic Heart Failure

Conditions

Interventions

DRUG

rhNRG-1

Subcutaneous Administration:0.6ug/kg/day for 10days

DRUG

rhNRG-1

Subcutaneous Administration 1.2ug/kg/day for 10 days

DRUG

rhNRG-1

Vein infusion:0.6ug/kg/day for 10 days

DRUG

placebo

Subcutaneous Administration:0.6 or 1.2ug/kg/day for 10days

Sponsors & Collaborators

  • Zensun Sci. & Tech. Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Runlin Gao · Cardiovascular Institute and Fuwai Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-07-31
Primary Completion
2011-01-31
Completion
2011-01-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01214096 on ClinicalTrials.gov